Rhythm Pharmaceuticals (RYTM) Financials

$61.36 -0.52 (-0.84%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$60.82 -0.53 (-0.87%)

As of 05/30/2025 05:55 PM Eastern

Annual Income Statements for Rhythm Pharmaceuticals

This table shows Rhythm Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-265	-185	-181	-70	-134	-281	-74	-38	-29	-12
Consolidated Net Income / (Loss)	-261	-185	-181	-70	-134	-141	-74	-34	-26	-11
Net Income / (Loss) Continuing Operations	-258	-184	-182	-70	-134	0.00	-74	-34	-26	-11
Total Pre-Tax Income	-260	-184	-181	-70	-134	-281	-74	-34	-26	-11
Total Operating Income	-266	-184	-179	-170	-137	-146	-78	-32	-26	-11
Total Gross Profit	117	68	22	2.56	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	130	77	24	3.15	0.00	0.00	0.00	0.00	0.00	0.00
Operating Revenue	130	77	24	3.15	0.00	0.00	-	-	-	-
Total Cost of Revenue	13	9.30	2.13	0.60	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	13	9.30	2.13	0.60	0.00	0.00	-	-	-	-
Total Operating Expenses	382	252	201	173	137	292	78	32	26	11
Selling, General & Admin Expense	144	118	92	68	46	37	28	9.52	6.31	3.43
Research & Development Expense	238	135	109	104	90	109	50	23	20	7.15
Total Other Income / (Expense), net	3.01	0.05	-1.17	100	2.58	11	4.35	-1.30	0.03	-0.50
Interest Expense	21	14	5.20	0.00	0.00	-	-	-	-	-
Interest & Investment Income	15	14	4.03	0.45	2.58	5.27	4.35	0.57	0.03	0.00
Other Income / (Expense), net	8.90	0.00	0.00	100	0.00	5.27	-	-1.86	0.00	-0.50
Income Tax Expense	0.35	0.56	0.00	0.00	-	-	-	-	-	-
Other Gains / (Losses), net	2.24	0.19	-0.79	-	-	-	-	-	-	-
Preferred Stock Dividends Declared	3.97	0.00	0.00	-	-	-	-	-	-	-
Basic Earnings per Share	($4.34)	($3.20)	($3.47)	($1.40)	($3.04)	($3.86)	($2.39)	($2.83)	($2.85)	($1.18)
Weighted Average Basic Shares Outstanding	61.00M	57.67M	52.12M	49.60M	44.13M	36.42M	31.00M	13.27M	10.20M	10.20M
Diluted Earnings per Share	($4.34)	($3.20)	$0.00	($1.40)	($3.04)	($3.86)	($2.39)	($2.83)	($2.85)	($1.18)
Weighted Average Diluted Shares Outstanding	61.00M	57.67M	0.00	49.60M	44.13M	36.42M	31.00M	13.27M	10.20M	10.20M
Weighted Average Basic & Diluted Shares Outstanding	63.22M	60.14M	56.75M	49.60M	44.13M	36.42M	31.00M	13.27M	10.20M	10.20M

This table shows Rhythm Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-51	-45	-45	-34	-141	-42	-44	-47	-52	-42	-41
Consolidated Net Income / (Loss)	-49	-43	-44	-32	-141	-42	-44	-47	-52	-42	-41
Net Income / (Loss) Continuing Operations	-49	-41	-44	-32	-141	-41	-44	-47	-52	-43	-41
Total Pre-Tax Income	-49	-43	-44	-32	-141	-41	-44	-47	-52	-42	-41
Total Operating Income	-47	-41	-44	-40	-140	-41	-44	-47	-53	-42	-39
Total Gross Profit	29	38	29	26	23	21	20	17	10	7.76	3.79
Total Revenue	33	42	33	29	26	24	23	19	11	8.79	4.28
Operating Revenue	33	42	33	29	26	24	23	19	11	8.79	4.28
Total Cost of Revenue	3.65	3.79	3.83	2.95	2.81	3.23	2.41	2.24	1.42	1.03	0.50
Operating Cost of Revenue	3.65	3.79	3.83	2.95	2.81	3.23	2.41	2.24	1.42	1.03	0.50
Total Operating Expenses	76	79	73	67	163	62	64	64	63	50	43
Selling, General & Admin Expense	39	38	35	36	34	32	30	30	25	26	22
Research & Development Expense	37	41	38	30	129	30	34	34	38	24	21
Total Other Income / (Expense), net	-2.41	-4.40	-0.10	8.70	-1.19	-0.36	0.16	-0.10	0.35	0.40	-1.59
Interest Expense	5.41	6.00	5.24	4.60	4.76	4.38	3.15	3.30	3.06	3.01	2.14
Interest & Investment Income	3.64	3.51	4.05	4.10	3.05	3.82	3.47	3.22	3.44	2.68	0.92
Other Income / (Expense), net	-0.64	-1.91	1.09	9.20	0.52	0.20	-0.16	-0.02	-0.03	0.74	-0.37
Income Tax Expense	0.08	-0.09	-0.34	0.48	0.30	0.20	0.37	0.00	0.00	-	0.00
Preferred Stock Dividends Declared	1.32	-	1.33	1.30	-	-	0.00	0.00	-	-	-
Basic Earnings per Share	($0.81)	($0.71)	($0.73)	($0.55)	($2.35)	($0.70)	($0.76)	($0.82)	($0.92)	($0.74)	($0.79)
Weighted Average Basic Shares Outstanding	63.06M	61.00M	61.22M	61.01M	60.14M	57.67M	57.87M	56.87M	56.71M	52.12M	51.40M
Diluted Earnings per Share	($0.81)	-	($0.73)	($0.55)	-	-	($0.76)	($0.82)	-	$2.73	($0.79)
Weighted Average Diluted Shares Outstanding	63.06M	61.00M	61.22M	61.01M	60.97M	57.67M	57.87M	56.87M	56.85M	0.00	51.40M
Weighted Average Basic & Diluted Shares Outstanding	63.62M	63.22M	61.46M	61.13M	60.97M	60.14M	59.10M	56.90M	56.85M	56.75M	56.35M

This table details how cash moves in and out of Rhythm Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	29	-68	68	-42	39	13	15	28	-28	35
Net Cash From Operating Activities	-114	-136	-173	-146	-122	-123	-62	-29	-23	-6.98
Net Cash From Continuing Operating Activities	-114	-136	-173	-146	-122	-123	-62	-29	-23	-6.98
Net Income / (Loss) Continuing Operations	-261	-185	-181	-70	-134	-141	-74	-34	-26	-11
Consolidated Net Income / (Loss)	-261	-185	-181	-70	-134	-141	-74	-34	-26	-11
Depreciation Expense	1.56	1.76	1.67	1.16	0.69	0.83	0.44	0.22	0.14	0.00
Amortization Expense	-8.17	-9.84	-2.31	0.00	0.00	-	-	-	-	-
Non-Cash Adjustments To Reconcile Net Income	144	52	26	-79	17	13	11	4.07	1.31	1.72
Changes in Operating Assets and Liabilities, net	9.16	4.62	-18	1.90	-5.90	4.13	0.67	-0.04	1.20	2.38
Net Cash From Investing Activities	-48	-5.67	28	-62	159	-28	-87	-110	-5.11	-0.02
Net Cash From Continuing Investing Activities	-48	-5.67	28	-62	159	-28	-87	-110	-5.11	-0.02
Purchase of Property, Plant & Equipment	0.00	-0.05	-0.28	-0.43	-0.21	-3.39	-0.72	-0.13	-1.06	-0.02
Acquisitions	-41	-5.67	0.00	0.00	-	-	-	-	-	-
Purchase of Investments	-268	-355	-252	-525	-87	-296	-249	-127	-15	0.00
Sale and/or Maturity of Investments	261	355	284	361	246	271	162	17	11	0.00
Other Investing Activities, net	0.00	0.00	-4.00	95	0.00	-	-	-	-	-
Net Cash From Financing Activities	191	74	214	166	2.01	163	165	167	0.00	42
Net Cash From Continuing Financing Activities	191	74	214	166	2.01	163	165	167	0.00	42
Repayment of Debt	-13	-7.40	0.00	0.00	-	-	-	-	-	-
Issuance of Debt	0.00	24	72	0.00	0.00	-	-	-	-	-
Issuance of Preferred Equity	139	0.00	0.00	-	-	-	-	0.70	0.00	40
Issuance of Common Equity	40	50	132	162	0.52	162	163	126	0.00	0.00
Other Financing Activities, net	25	7.47	9.75	4.13	1.49	1.56	1.81	41	0.00	2.09
Effect of Exchange Rate Changes	0.00	-0.14	0.00	0.00	-	-	-	-	-	-

This table details how cash moves in and out of Rhythm Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	17	42	-114	108	-6.52	-4.51	-51	6.02	-18	-57	72
Net Cash From Operating Activities	-40	-19	-25	-29	-41	-29	-29	-41	-36	-34	-47
Net Cash From Continuing Operating Activities	-40	-19	-25	-29	-41	-29	-29	-41	-36	-34	-47
Net Income / (Loss) Continuing Operations	-49	-43	-44	-32	-141	-42	-44	-47	-52	-42	-41
Consolidated Net Income / (Loss)	-49	-43	-44	-32	-141	-42	-44	-47	-52	-42	-41
Depreciation Expense	0.38	0.38	0.39	0.39	0.41	0.42	0.44	0.44	0.46	0.44	0.44
Amortization Expense	-1.79	-2.14	-2.47	-5.52	1.95	-9.84	4.30	-5.02	0.72	-4.50	2.14
Non-Cash Adjustments To Reconcile Net Income	18	16	16	11	101	13	12	15	12	11	5.77
Changes in Operating Assets and Liabilities, net	-7.83	10	4.19	-2.45	-2.68	8.87	-1.71	-5.25	2.70	1.95	-14
Net Cash From Investing Activities	25	21	-91	-8.56	30	23	-95	48	18	-41	-40
Net Cash From Continuing Investing Activities	25	21	-91	-8.56	30	23	-95	48	18	-41	-40
Acquisitions	0.00	-	-0.50	-	-40	-	-0.27	-0.88	-4.52	-	-
Purchase of Investments	-34	-66	-136	-66	0.00	-41	-169	-75	-70	-100	-101
Sale and/or Maturity of Investments	58	88	45	58	70	63	75	125	93	60	61
Net Cash From Financing Activities	32	38	2.49	146	4.24	2.42	73	-0.97	-0.13	17	159
Net Cash From Continuing Financing Activities	32	38	2.49	146	4.24	2.42	73	-0.97	-0.13	17	159
Repayment of Debt	-4.62	-3.81	-3.34	-2.97	-2.78	-2.57	-2.17	-1.31	-1.35	-	-
Issuance of Common Equity	35	39	0.60	-	0.67	-	49	-	0.67	14	117
Other Financing Activities, net	2.23	2.99	5.23	10	6.35	5.00	1.58	0.34	0.55	5.89	3.86
Effect of Exchange Rate Changes	-0.00	0.98	-0.60	-0.30	-0.07	-0.19	0.08	-0.11	0.09	-	-

This table presents Rhythm Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2017	12/31/2016
Total Assets	392	333	382	330	187	309	152	12
Total Current Assets	374	308	354	308	182	302	151	11
Cash & Equivalents	89	60	128	59	101	62	34	6.54
Restricted Cash	0.46	-	-	-	-	-	-	-
Short-Term Investments	231	216	206	236	72	230	114	4.00
Accounts Receivable	19	15	6.22	1.03	-	-	-	-
Inventories, net	19	8.62	2.92	0.11	-	-	-	-
Prepaid Expenses	16	8.93	12	12	8.88	9.95	2.59	0.64
Plant, Property, & Equipment, net	0.63	1.34	2.20	2.81	3.20	3.67	0.84	0.93
Total Noncurrent Assets	17	23	26	18	2.21	2.45	0.23	0.23
Long-Term Investments	7.33	15	17	12	-	-	-	-
Intangible Assets	6.17	7.03	7.88	4.66	0.00	-	-	-
Other Noncurrent Operating Assets	3.48	1.11	1.51	1.85	2.21	2.45	0.23	0.23
Total Liabilities & Shareholders' Equity	392	333	382	330	187	309	152	12
Total Liabilities	228	163	118	45	21	28	6.95	5.04
Total Current Liabilities	116	55	40	43	18	24	6.72	4.73
Short-Term Debt	1.54	0.00	-	-	-	-	-	-
Accounts Payable	12	4.89	4.80	5.74	4.90	10	2.43	2.00
Accrued Expenses	63	48	33	30	13	14	4.21	2.66
Current Deferred Revenue	1.29	1.29	1.43	7.00	-	-	0.08	0.08
Other Current Liabilities	38	0.77	0.68	0.61	0.54	0.47	-	-
Total Noncurrent Liabilities	112	108	78	1.95	2.55	3.09	0.23	0.31
Long-Term Debt	108	106	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	3.94	1.64	2.60	1.95	2.55	3.09	-	-
Commitments & Contingencies	0.00	0.00	-	-	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	143	0.00	-	-	-	-	0.00	40
Total Equity & Noncontrolling Interests	22	170	264	284	167	281	145	-33
Total Preferred & Common Equity	22	170	264	284	167	281	145	-33
Total Common Equity	22	170	264	284	167	281	145	-33
Common Stock	1,177	1,064	974	813	626	606	255	44
Retained Earnings	-1,155	-895	-710	-529	-459	-325	-110	-77
Accumulated Other Comprehensive Income / (Loss)	-0.04	0.13	-0.09	-0.00	0.05	0.00	-	-

This table presents Rhythm Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	387	364	382	259	354	310	346	390
Total Current Assets	369	340	357	236	329	284	318	362
Cash & Equivalents	106	48	162	53	65	116	110	185
Restricted Cash	0.46	0.46	0.46	-	-	-	-	-
Short-Term Investments	208	251	157	148	235	138	185	163
Accounts Receivable	18	19	18	15	15	14	8.12	3.33
Inventories, net	19	14	12	8.51	7.76	6.18	5.49	-
Prepaid Expenses	18	8.75	8.64	11	7.64	10	9.65	11
Plant, Property, & Equipment, net	0.46	0.80	0.97	1.15	1.55	1.77	2.00	2.43
Total Noncurrent Assets	16	22	23	22	23	24	26	25
Long-Term Investments	7.14	12	13	14	15	16	17	16
Intangible Assets	5.96	6.39	6.60	6.82	7.24	7.46	7.67	8.10
Other Noncurrent Operating Assets	3.37	3.59	3.70	1.13	1.22	1.32	1.42	1.60
Total Liabilities & Shareholders' Equity	387	364	382	259	354	310	346	390
Total Liabilities	224	211	202	197	157	128	126	108
Total Current Liabilities	112	98	55	54	50	46	46	33
Short-Term Debt	1.59	-	-	-	-	-	-	-
Accounts Payable	12	4.89	4.54	7.55	3.84	8.38	13	4.93
Accrued Expenses	59	55	48	45	44	36	31	26
Current Deferred Revenue	0.00	1.29	1.29	1.29	1.29	1.29	1.43	1.76
Other Current Liabilities	39	37	1.18	0.79	0.75	0.73	0.71	0.66
Total Noncurrent Liabilities	112	113	147	143	107	82	80	75
Long-Term Debt	108	-	-	-	-	-	-	73
Other Noncurrent Operating Liabilities	3.84	4.03	39	36	1.88	2.21	2.37	2.36
Commitments & Contingencies	0.00	0.00	0.00	-	-	-	-	-
Redeemable Noncontrolling Interest	144	141	140	-	-	-	-	-
Total Equity & Noncontrolling Interests	19	11	39	62	197	182	220	281
Total Preferred & Common Equity	19	11	39	62	197	182	220	281
Total Common Equity	19	11	39	62	197	182	220	281
Common Stock	1,224	1,124	1,108	1,098	1,051	991	982	949
Retained Earnings	-1,205	-1,112	-1,068	-1,036	-853	-809	-762	-668
Accumulated Other Comprehensive Income / (Loss)	-0.05	-0.60	-0.62	-0.18	-0.11	-0.01	-0.01	-0.34

This table displays calculated financial ratios and metrics derived from Rhythm Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	68.06%	227.56%	649.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-36.78%	-7.03%	-160.95%	49.29%	2.87%	-79.41%	-128.99%	-32.18%	-132.65%	0.00%
EBIT Growth	-39.19%	-2.90%	-155.72%	48.70%	2.95%	-79.46%	-128.79%	-32.31%	-133.95%	0.00%
NOPAT Growth	-44.02%	-2.90%	-5.35%	-24.52%	6.46%	-86.18%	-141.94%	-25.12%	-145.01%	0.00%
Net Income Growth	-41.11%	-1.97%	-160.18%	48.05%	4.78%	-90.01%	-119.72%	-30.29%	-133.65%	0.00%
EPS Growth	-35.63%	0.00%	100.00%	53.95%	21.24%	-61.51%	15.55%	0.70%	-141.53%	0.00%
Operating Cash Flow Growth	16.36%	21.49%	-18.78%	-19.69%	0.63%	-97.81%	-110.64%	-26.88%	-232.79%	0.00%
Free Cash Flow Firm Growth	26.52%	-220.96%	39.44%	-1.99%	-11.04%	-55.98%	-156.97%	-52.13%	0.00%	0.00%
Invested Capital Growth	-261.35%	82.56%	-280.48%	-259.50%	45.24%	0.00%	100.00%	-1.39%	0.00%	0.00%
Revenue Q/Q Growth	15.64%	24.92%	41.84%	135.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-3.13%	-5.28%	2.83%	-29.68%	-19,429.30%	-16,423.80%	-25.85%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-0.90%	0.59%	5.10%	-29.40%	0.00%	0.00%	-25.97%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.01%	0.45%	4.73%	-10.33%	0.00%	0.00%	-25.97%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-0.65%	0.46%	0.21%	-12.93%	0.00%	0.00%	-25.35%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	100.00%	-9.38%	0.00%	0.00%	-106.03%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	8.47%	3.28%	3.60%	-8.43%	2.48%	-10.08%	-26.75%	-6.15%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-1.59%	-803.70%	55.22%	-6.93%	-1,713.52%	-1,285.64%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	65.86%	87.20%	-825.78%	-35.46%	-29.23%	-9.95%	100.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.73%	87.99%	90.98%	81.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-202.27%	-248.53%	-760.64%	-2,184.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-204.04%	-238.10%	-757.92%	-5,391.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-197.20%	-238.10%	-757.92%	-2,221.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-200.27%	-238.52%	-766.22%	-2,207.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.13%	100.31%	100.00%	100.00%	100.00%	50.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	101.42%	99.87%	101.10%	99.36%	98.11%	200.00%	94.45%	98.35%	99.87%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-155.91%	-85.10%	-66.05%	-30.89%	-59.88%	-100.16%	-102.31%	-44.33%	-354.56%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-70.79%	-51.55%	-50.32%	-27.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-71.89%	-51.64%	-50.88%	-26.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-89.30%	-85.10%	-66.05%	-30.89%	-59.88%	-100.16%	-102.31%	-32.67%	1,589.02%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-1,199.33%	-108.79%	-68.54%	-24.50%	-80.46%	-50.08%	0.00%	-23.28%	79.11%	0.00%
Net Operating Profit after Tax (NOPAT)	-186	-129	-125	-119	-96	-102	-55	-23	-18	-7.40
NOPAT Margin	-142.82%	-166.67%	-530.54%	-3,774.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-37.07%	-20.81%	-16.97%	20.62%	-16.50%	-26.35%	-25.89%	-13.89%	-146.76%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-141.29%	-46.77%	-47.46%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	10.27%	12.01%	9.02%	18.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	110.90%	151.80%	389.34%	2,171.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	182.87%	174.29%	459.56%	3,301.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	293.76%	326.09%	848.90%	5,472.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-257	-184	-179	-70	-137	-141	-78	-34	-26	-11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-263	-192	-180	-69	-136	-140	-78	-34	-26	-11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	158.33	16.00	6.21	1.77	7.89	3.59	0.00	5.48	0.00	0.00
Price to Tangible Book Value (P/TBV)	221.17	16.69	6.40	1.80	7.89	3.59	0.00	5.48	0.00	0.00
Price to Revenue (P/Rev)	26.44	35.09	69.42	159.06	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	25.86	32.70	54.61	61.83	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.67	0.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.66	0.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.21	-1.23	-1.20	-1.06	-1.04	-1.04	-1.02	-1.04	-1.45	0.00
Leverage Ratio	2.17	1.65	1.30	1.15	1.11	1.10	1.05	1.08	1.69	0.00
Compound Leverage Factor	2.20	1.65	1.31	1.14	1.09	2.20	0.99	1.06	1.69	0.00
Debt to Total Capital	40.02%	38.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	39.46%	38.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	52.06%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	548.17%	0.00%
Common Equity to Total Capital	7.92%	61.53%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	-448.17%	0.00%
Debt to EBITDA	-0.42	-0.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.83	0.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.41	-0.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.59	-0.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.18	1.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.58	-0.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	3.91	5.55	5.23	4.66	33.58	20.10	0.00	67.85	0.00	0.00
Noncontrolling Interest Sharing Ratio	42.72%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	26.30%	548.17%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.24	5.58	8.90	7.10	10.10	12.39	0.00	22.42	2.36	0.00
Quick Ratio	2.94	5.27	8.53	6.81	9.60	11.98	0.00	22.04	2.23	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-147	-200	-62	-103	-101	-91	-58	-23	-15	0.00
Operating Cash Flow to CapEx	0.00%	-289,695.74%	-61,718.15%	-33,641.24%	-57,000.00%	-3,626.29%	-8,595.01%	-22,150.38%	-2,196.69%	-41,041.18%
Free Cash Flow to Firm to Interest Expense	-7.13	-14.38	-11.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-5.53	-9.80	-33.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-5.53	-9.80	-33.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.22	0.07	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	7.80	7.34	6.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.98	1.61	1.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	131.91	43.77	9.44	1.05	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	1.55	1.92	0.41	0.11	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	46.81	49.71	55.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	373.59	226.43	259.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	234.99	189.96	901.29	3,240.82	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	185.41	86.18	-586.25	-3,240.82	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-54	-15	-86	-23	-6.26	-11	0.00	-3.29	-3.25	0.00
Invested Capital Turnover	-3.78	-1.54	-0.44	-0.22	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-39	71	-63	-16	5.18	-11	3.29	-0.05	-3.25	0.00
Enterprise Value (EV)	3,365	2,532	1,291	195	1,141	716	925	645	0.00	0.00
Market Capitalization	3,440	2,717	1,641	502	1,314	1,009	925	793	0.00	0.00
Book Value per Share	$0.35	$2.87	$4.69	$5.65	$3.77	$6.40	$0.00	$5.31	($3.21)	$0.00
Tangible Book Value per Share	$0.25	$2.75	$4.55	$5.56	$3.77	$6.40	$0.00	$5.31	($3.21)	$0.00
Total Capital	274	276	264	284	167	281	0.00	145	7.30	0.00
Total Debt	110	106	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	108	106	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-219	-185	-350	-307	-173	-292	0.00	-148	-11	0.00
Capital Expenditures (CapEx)	0.00	0.05	0.28	0.43	0.21	3.39	0.72	0.13	1.06	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-61	-23	-19	-30	-9.12	-14	0.00	-4.13	-4.09	0.00
Debt-free Net Working Capital (DFNWC)	260	253	314	265	164	278	0.00	144	6.44	0.00
Net Working Capital (NWC)	259	253	314	265	164	278	0.00	144	6.44	0.00
Net Nonoperating Expense (NNE)	75	56	56	-49	38	39	19	11	7.74	3.67
Net Nonoperating Obligations (NNO)	-219	-185	-350	-307	-173	-292	0.00	-148	-11	0.00
Total Depreciation and Amortization (D&A)	-6.60	-8.08	-0.64	1.16	0.69	0.83	0.44	0.22	0.14	0.00
Debt-free, Cash-free Net Working Capital to Revenue	-46.73%	-29.42%	-79.79%	-947.84%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	199.98%	326.84%	1,330.18%	8,400.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	198.79%	326.84%	1,330.18%	8,400.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.34)	($3.20)	($3.47)	($1.40)	($3.04)	$0.00	($2.39)	($2.83)	($2.85)	($1.18)
Adjusted Weighted Average Basic Shares Outstanding	61.00M	57.67M	52.12M	49.60M	50.18M	0.00	34.43M	27.28M	10.20M	10.20M
Adjusted Diluted Earnings per Share	($4.34)	($3.20)	($3.47)	($1.40)	($3.04)	$0.00	($2.39)	($2.83)	($2.85)	($1.18)
Adjusted Weighted Average Diluted Shares Outstanding	61.00M	57.67M	52.12M	49.60M	50.18M	0.00	34.43M	27.28M	10.20M	10.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($3.04)	$0.00	($2.39)	($2.83)	($2.85)	($1.18)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	63.22M	60.14M	56.75M	49.60M	44.13M	0.00	31.00M	13.27M	10.20M	10.20M
Normalized Net Operating Profit after Tax (NOPAT)	-186	-129	-125	-119	-96	-102	-55	-23	-18	-7.40
Normalized NOPAT Margin	-142.82%	-166.67%	-530.54%	-3,774.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-200.00%	-237.79%	-766.22%	-2,207.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-12.45	-13.27	-34.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-9.02	-9.29	-24.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-12.45	-13.27	-34.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-9.02	-9.29	-24.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Rhythm Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	25.94%	72.61%	47.76%	51.28%	126.41%	175.70%	425.30%	112.01%	665.62%	383.76%	316.73%
EBITDA Growth	65.04%	11.02%	-13.98%	28.90%	-166.64%	-11.13%	-6.26%	-14.42%	2.27%	10.33%	15.65%
EBIT Growth	65.81%	-5.12%	2.98%	32.91%	-165.16%	0.73%	-11.29%	-3.08%	0.69%	18.87%	10.40%
NOPAT Growth	66.40%	0.04%	0.15%	13.14%	-166.29%	1.98%	-11.93%	-3.34%	0.30%	17.43%	11.24%
Net Income Growth	64.99%	-4.07%	1.18%	30.92%	-170.94%	2.02%	-8.08%	-3.78%	1.11%	0.87%	-16.39%
EPS Growth	65.53%	0.00%	3.95%	32.93%	0.00%	0.00%	3.80%	7.87%	0.00%	403.33%	-12.86%
Operating Cash Flow Growth	0.96%	35.86%	13.80%	29.24%	-11.83%	13.58%	37.75%	-5.88%	32.07%	15.99%	-17.00%
Free Cash Flow Firm Growth	-279.36%	110.21%	-86.13%	15.11%	-215.43%	-395.72%	320.22%	223.28%	184.15%	273.33%	-81.63%
Invested Capital Growth	67.75%	-261.35%	-35.42%	-76.02%	-67.54%	82.56%	-1,161.82%	-304.24%	-288.83%	-280.48%	44.33%
Revenue Q/Q Growth	-21.82%	25.80%	14.35%	11.98%	7.15%	7.69%	17.08%	67.59%	30.48%	105.18%	-52.75%
EBITDA Q/Q Growth	-9.19%	-0.10%	-23.28%	73.43%	-196.06%	-28.23%	23.10%	0.36%	-25.84%	-22.61%	17.20%
EBIT Q/Q Growth	-10.38%	-0.86%	-36.84%	77.56%	-240.94%	6.91%	5.38%	11.30%	-24.67%	-4.36%	12.36%
NOPAT Q/Q Growth	-13.94%	6.00%	-8.42%	71.06%	-238.96%	6.11%	5.69%	11.28%	-24.77%	-7.22%	12.93%
Net Income Q/Q Growth	-14.24%	0.72%	-35.27%	77.18%	-239.57%	5.73%	5.44%	10.49%	-22.79%	-3.99%	9.20%
EPS Q/Q Growth	0.00%	0.00%	-32.73%	0.00%	0.00%	0.00%	7.32%	0.00%	0.00%	445.57%	11.24%
Operating Cash Flow Q/Q Growth	-114.12%	25.26%	13.28%	28.64%	-38.66%	-0.45%	28.81%	-12.78%	-7.16%	27.64%	-21.07%
Free Cash Flow Firm Q/Q Growth	-1,444.76%	-4.43%	-71.74%	204.45%	-653.53%	-229.79%	134.51%	4.74%	-7.24%	196.65%	-31.28%
Invested Capital Q/Q Growth	8.36%	65.86%	-3.47%	0.38%	-26.71%	87.20%	-34.49%	5.17%	-6.88%	-825.78%	56.92%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.85%	90.95%	88.49%	89.87%	89.19%	86.66%	89.28%	88.37%	87.61%	88.30%	88.40%
EBITDA Margin	-149.99%	-107.39%	-134.96%	-125.19%	-527.61%	-208.32%	-174.95%	-266.36%	-448.00%	-516.83%	-864.87%
Operating Margin	-143.73%	-98.62%	-131.98%	-139.20%	-538.71%	-170.29%	-195.31%	-242.46%	-458.03%	-478.99%	-916.60%
EBIT Margin	-145.69%	-103.20%	-128.71%	-107.56%	-536.69%	-169.46%	-196.02%	-242.55%	-458.26%	-470.61%	-925.23%
Profit (Net Income) Margin	-151.35%	-103.58%	-131.25%	-110.95%	-544.43%	-171.80%	-196.25%	-242.98%	-454.96%	-483.42%	-953.80%
Tax Burden Percent	100.16%	99.80%	99.22%	101.51%	100.21%	100.47%	100.84%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	103.71%	100.58%	102.78%	101.62%	101.23%	100.90%	99.28%	100.18%	99.28%	102.72%	103.09%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-150.20%	-155.91%	-147.88%	-143.42%	-194.69%	-85.10%	-77.52%	-96.44%	-79.26%	-66.05%	-60.15%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-61.80%	-37.04%	-40.36%	-31.65%	-163.28%	-36.69%	-32.67%	-36.13%	-48.86%	-31.25%	-41.37%
Return on Assets (ROA)	-64.20%	-37.18%	-41.15%	-32.65%	-165.63%	-37.20%	-32.71%	-36.19%	-48.50%	-32.10%	-42.65%
Return on Common Equity (ROCE)	-53.84%	-89.30%	-88.13%	-87.86%	-194.69%	-85.10%	-77.52%	-96.44%	-79.26%	-66.05%	-60.15%
Return on Equity Simple (ROE_SIMPLE)	-890.53%	0.00%	-2,308.58%	-659.40%	-444.73%	0.00%	-93.96%	-99.97%	-82.15%	0.00%	-64.54%
Net Operating Profit after Tax (NOPAT)	-33	-29	-31	-28	-98	-29	-31	-33	-37	-29	-27
NOPAT Margin	-100.61%	-69.03%	-92.39%	-97.44%	-377.10%	-119.21%	-136.72%	-169.72%	-320.62%	-335.29%	-641.62%
Net Nonoperating Expense Percent (NNEP)	-7.76%	-7.17%	-4.13%	-1.31%	-16.51%	-4.77%	-4.43%	-5.79%	-5.40%	-3.97%	-4.25%
Return On Investment Capital (ROIC_SIMPLE)	-25.61%	-21.95%	-	-	-	-10.47%	-	-	-	-11.15%	-
Cost of Revenue to Revenue	11.15%	9.05%	11.51%	10.13%	10.81%	13.34%	10.72%	11.63%	12.39%	11.70%	11.60%
SG&A Expenses to Revenue	119.52%	91.15%	106.39%	125.23%	132.41%	133.60%	135.42%	156.32%	214.79%	299.40%	512.09%
R&D to Revenue	113.05%	98.42%	114.07%	103.84%	495.49%	123.35%	149.17%	174.51%	330.85%	267.90%	492.90%
Operating Expenses to Revenue	232.57%	189.57%	220.47%	229.07%	627.90%	256.95%	284.59%	330.83%	545.64%	567.29%	1,005.00%
Earnings before Interest and Taxes (EBIT)	-48	-43	-43	-31	-139	-41	-44	-47	-53	-41	-40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-49	-45	-45	-36	-137	-50	-39	-51	-51	-45	-37
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	176.75	158.33	285.58	63.63	42.32	16.00	6.61	5.14	4.61	6.21	4.42
Price to Tangible Book Value (P/TBV)	257.87	221.17	663.52	76.46	47.58	16.69	6.86	5.36	4.77	6.40	4.55
Price to Revenue (P/Rev)	24.47	26.44	28.46	24.60	28.35	35.09	21.05	21.42	30.12	69.42	74.57
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.97	25.86	26.96	22.71	26.01	32.70	15.98	15.27	20.86	54.61	57.14
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.67	0.67	0.00	0.00	0.00	0.63	0.00	0.00	0.00	0.00	0.26
Long-Term Debt to Equity	0.66	0.66	0.00	0.00	0.00	0.63	0.00	0.00	0.00	0.00	0.26
Financial Leverage	-1.90	-1.21	-1.79	-1.66	-1.87	-1.23	-1.26	-1.29	-1.25	-1.20	-1.04
Leverage Ratio	2.87	2.17	2.05	1.91	2.15	1.65	1.55	1.55	1.38	1.30	1.24
Compound Leverage Factor	2.98	2.18	2.11	1.94	2.17	1.66	1.54	1.56	1.37	1.33	1.27
Debt to Total Capital	40.18%	40.02%	0.00%	0.00%	0.00%	38.47%	0.00%	0.00%	0.00%	0.00%	20.60%
Short-Term Debt to Total Capital	0.58%	0.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	39.59%	39.46%	0.00%	0.00%	0.00%	38.47%	0.00%	0.00%	0.00%	0.00%	20.60%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	52.87%	52.06%	92.66%	78.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	6.95%	7.92%	7.34%	21.92%	100.00%	61.53%	100.00%	100.00%	100.00%	100.00%	79.40%
Debt to EBITDA	-0.64	-0.42	0.00	0.00	0.00	-0.55	0.00	0.00	0.00	0.00	-0.39
Net Debt to EBITDA	1.24	0.83	0.00	0.00	0.00	0.96	0.00	0.00	0.00	0.00	1.57
Long-Term Debt to EBITDA	-0.63	-0.41	0.00	0.00	0.00	-0.55	0.00	0.00	0.00	0.00	-0.39
Debt to NOPAT	-0.91	-0.59	0.00	0.00	0.00	-0.82	0.00	0.00	0.00	0.00	-0.55
Net Debt to NOPAT	1.76	1.18	0.00	0.00	0.00	1.43	0.00	0.00	0.00	0.00	2.21
Long-Term Debt to NOPAT	-0.89	-0.58	0.00	0.00	0.00	-0.82	0.00	0.00	0.00	0.00	-0.55
Altman Z-Score	5.37	5.70	5.55	4.45	1.75	6.97	2.33	1.32	2.28	6.42	5.20
Noncontrolling Interest Sharing Ratio	64.16%	42.72%	40.40%	38.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.30	3.24	3.49	6.53	4.35	5.58	6.57	6.16	6.91	8.90	10.93
Quick Ratio	2.97	2.94	3.25	6.15	3.99	5.27	6.26	5.80	6.58	8.53	10.61
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-137	10	11	38	-36	-100	77	33	31	34	-35
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,925,100.00%	0.00%	-77,517.02%	0.00%	-49,460.00%
Free Cash Flow to Firm to Interest Expense	-25.30	1.70	2.03	8.19	-7.59	-22.75	24.38	9.91	10.21	11.19	-16.26
Operating Cash Flow to Interest Expense	-7.46	-3.14	-4.81	-6.32	-8.57	-6.71	-9.29	-12.44	-11.90	-11.29	-21.92
Operating Cash Flow Less CapEx to Interest Expense	-7.46	-3.14	-4.81	-6.32	-8.57	-6.71	-9.29	-12.44	-11.92	-11.29	-21.96
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.42	0.36	0.31	0.29	0.30	0.22	0.17	0.15	0.11	0.07	0.04
Accounts Receivable Turnover	8.42	7.80	6.65	6.48	8.06	7.34	6.94	5.63	7.49	6.52	0.00
Inventory Turnover	1.02	0.98	1.18	1.25	1.53	1.61	0.00	0.00	0.00	1.41	0.00
Fixed Asset Turnover	169.91	131.91	95.93	74.13	58.37	43.77	31.22	20.21	14.23	9.44	6.19
Accounts Payable Turnover	1.46	1.55	2.94	1.76	1.02	1.92	1.62	0.72	0.26	0.41	0.28
Days Sales Outstanding (DSO)	43.36	46.81	54.89	56.35	45.29	49.71	52.61	64.79	48.76	55.97	0.00
Days Inventory Outstanding (DIO)	357.36	373.59	308.42	290.94	238.95	226.43	0.00	0.00	0.00	259.08	0.00
Days Payable Outstanding (DPO)	249.97	234.99	124.27	206.95	356.82	189.96	225.57	506.96	1,392.19	901.29	1,299.27
Cash Conversion Cycle (CCC)	150.75	185.41	239.04	140.34	-72.58	86.18	-172.96	-442.17	-1,343.44	-586.25	-1,299.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-49	-54	-158	-153	-153	-15	-117	-87	-92	-86	-9.26
Invested Capital Turnover	-1.35	-3.78	-0.82	-0.85	-0.75	-1.54	-0.98	-0.81	-0.58	-0.44	-1.29
Increase / (Decrease) in Invested Capital	104	-39	-41	-66	-62	71	-108	-65	-68	-63	7.37
Enterprise Value (EV)	3,281	3,365	3,033	2,311	2,391	2,532	990	668	701	1,291	952
Market Capitalization	3,349	3,440	3,203	2,504	2,606	2,717	1,304	938	1,012	1,641	1,243
Book Value per Share	$0.30	$0.35	$0.18	$0.65	$1.02	$2.87	$3.47	$3.21	$3.87	$4.69	$5.54
Tangible Book Value per Share	$0.21	$0.25	$0.08	$0.54	$0.91	$2.75	$3.34	$3.08	$3.74	$4.55	$5.38
Total Capital	273	274	153	179	62	276	197	182	220	264	354
Total Debt	110	110	0.00	0.00	0.00	106	0.00	0.00	0.00	0.00	73
Total Long-Term Debt	108	108	0.00	0.00	0.00	106	0.00	0.00	0.00	0.00	73
Net Debt	-213	-219	-311	-332	-215	-185	-314	-269	-311	-350	-290
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	-0.00	0.00	0.00	0.05	-0.00	0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-56	-61	-56	-17	-20	-23	-20	-16	-23	-19	-19
Debt-free Net Working Capital (DFNWC)	259	260	243	303	182	253	279	238	272	314	329
Net Working Capital (NWC)	257	259	243	303	182	253	279	238	272	314	329
Net Nonoperating Expense (NNE)	17	14	13	3.93	43	13	13	14	15	13	13
Net Nonoperating Obligations (NNO)	-213	-219	-311	-332	-215	-185	-314	-269	-311	-350	-290
Total Depreciation and Amortization (D&A)	-1.40	-1.76	-2.08	-5.13	2.36	-9.42	4.74	-4.58	1.18	-4.06	2.59
Debt-free, Cash-free Net Working Capital to Revenue	-40.84%	-46.73%	-49.87%	-16.65%	-21.33%	-29.42%	-32.59%	-36.16%	-67.76%	-79.79%	-114.13%
Debt-free Net Working Capital to Revenue	189.28%	199.98%	215.71%	297.34%	197.54%	326.84%	450.21%	543.31%	808.74%	1,330.18%	1,972.85%
Net Working Capital to Revenue	188.12%	198.79%	215.71%	297.34%	197.54%	326.84%	450.21%	543.31%	808.74%	1,330.18%	1,972.85%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.81)	($0.71)	($0.73)	($0.55)	($2.35)	($0.70)	($0.76)	($0.82)	($0.92)	($0.74)	($0.79)
Adjusted Weighted Average Basic Shares Outstanding	63.06M	61.00M	61.22M	61.01M	60.14M	57.67M	57.87M	56.87M	56.71M	52.12M	51.40M
Adjusted Diluted Earnings per Share	($0.81)	$0.00	($0.73)	($0.55)	$0.00	$0.00	($0.76)	($0.82)	($0.92)	$2.73	($0.79)
Adjusted Weighted Average Diluted Shares Outstanding	63.06M	61.00M	61.22M	61.01M	60.97M	57.67M	57.87M	56.87M	56.71M	0.00	51.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	63.62M	63.22M	61.46M	61.13M	60.97M	60.14M	59.10M	56.90M	56.85M	56.75M	56.35M
Normalized Net Operating Profit after Tax (NOPAT)	-33	-29	-31	-28	-98	-29	-31	-33	-37	-29	-27
Normalized NOPAT Margin	-100.61%	-69.03%	-92.39%	-97.44%	-377.10%	-119.21%	-136.72%	-169.72%	-320.62%	-335.29%	-641.62%
Pre Tax Income Margin	-151.11%	-103.79%	-132.28%	-109.30%	-543.27%	-170.99%	-194.61%	-242.98%	-454.96%	-483.42%	-953.80%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.81	-7.19	-8.16	-6.79	-29.31	-9.38	-14.01	-14.11	-17.17	-13.74	-18.49
NOPAT to Interest Expense	-6.08	-4.81	-5.86	-6.16	-20.59	-6.60	-9.77	-9.88	-12.01	-9.79	-12.82
EBIT Less CapEx to Interest Expense	-8.81	-7.19	-8.16	-6.79	-29.31	-9.38	-14.01	-14.11	-17.19	-13.74	-18.53
NOPAT Less CapEx to Interest Expense	-6.08	-4.81	-5.86	-6.16	-20.59	-6.60	-9.77	-9.88	-12.03	-9.79	-12.86
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Rhythm Pharmaceuticals' Financials

When does Rhythm Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Rhythm Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Rhythm Pharmaceuticals' net income changed over the last 9 years?

Rhythm Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$260.60 million in 2024, rising from -$11.07 million in 2015. The previous period was -$184.68 million in 2023. Check out Rhythm Pharmaceuticals' forecast to explore projected trends and price targets.

What is Rhythm Pharmaceuticals's operating income?

Rhythm Pharmaceuticals's total operating income in 2024 was -$265.50 million, based on the following breakdown:

Total Gross Profit: $116.76 million
Total Operating Expenses: $382.26 million

How has Rhythm Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Rhythm Pharmaceuticals' total revenue changed from $0.00 in 2015 to $130.13 million in 2024, a change of 13,012,600,000.0%.

How much debt does Rhythm Pharmaceuticals have?

Rhythm Pharmaceuticals' total liabilities were at $227.72 million at the end of 2024, a 39.7% increase from 2023, and a 4,416.5% increase since 2016.

How much cash does Rhythm Pharmaceuticals have?

In the past 7 years, Rhythm Pharmaceuticals' cash and equivalents has ranged from $6.54 million in 2016 to $127.68 million in 2022, and is currently $89.14 million as of their latest financial filing in 2024.

How has Rhythm Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Rhythm Pharmaceuticals' book value per share changed from 0.00 in 2015 to 0.35 in 2024, a change of 35.4%.

Related Companies

This page (NASDAQ:RYTM) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Financials

Frequently Asked Questions About Rhythm Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Financials

Annual Income Statements for Rhythm Pharmaceuticals

Quarterly Income Statements for Rhythm Pharmaceuticals

Annual Cash Flow Statements for Rhythm Pharmaceuticals

Quarterly Cash Flow Statements for Rhythm Pharmaceuticals

Annual Balance Sheets for Rhythm Pharmaceuticals

Quarterly Balance Sheets for Rhythm Pharmaceuticals

Annual Metrics And Ratios for Rhythm Pharmaceuticals

Quarterly Metrics And Ratios for Rhythm Pharmaceuticals

Frequently Asked Questions About Rhythm Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools